@FierceMedDev: Profit stumble pushes Philips to focus on healthcare. Article | Follow @FierceMedDev
@StacyALawrence: Miss Idaho wears insulin pump in swimsuit competition. Item | Follow @StacyALawrence
@VarunSaxena2: ICYMI yesterday: FDA approves expandable implant for spinal fusion surgery. News | Follow @VarunSaxena2
@MichaelGFierce: RT @EmilyMFierce: Which 15 disease areas get the most funding from NIH? Report | Follow @MichaelGFierce
@EmilyWFierce: Auditory brainstem implant provides alternative to cochlear device, offers profoundly deaf children a chance to hear. More from the Los Angeles Times | Follow @EmilyWFierce
> Thermo Fisher Scientific ($TMO) sold its Cole-Parmer laboratory division to private equity firm GTCR for $480 million. Story
> Dental laser company Biolase to raise $12 million in a private placement with investors including Oracle Partners and Birchview Capital. Release
> USGI Medical garnered a $9 million line of credit from GE Capital to help support its pivotal trial for its endospopic obesity device. Release
Biotech News
@FierceBiotech: $ZIOP, $XON tackle CAR-T in expanded partnership. More | Follow @FierceBiotech
@JohnCFierce: Biosimilars set to boom as new patent cliff on biologic superstars looms. Article | Follow @JohnCFierce
@DamianFierce: "It's like surfing. If you aren't in the water you'll never catch that monster wave." -- $ZAFG CEO on going public. More | Follow @DamianFierce
@EmilyMFierce: Which 15 disease areas get the most funding from NIH? List | Follow @EmilyMFierce
> AstraZeneca adds Advaxis to a growing roster of immuno-oncology partners. Story
> With a $650M gift and a trove of genomic data, Broad sets out to innovate in schizophrenia. Article
> Sage takes to the FDA fast track with its lead rare disease drug. News
> Atlas, NEA bankroll a $30M round for synthetic biology upstart Synlogic. Report
Pharma News
@FiercePharma: Top-read on FP Monday: Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong. Article | Follow @FiercePharma
@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Story | Follow @TracyStaton
@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. More from FierceAnimalHealth | Follow @EricPFierce
@CarlyHFierce: Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Report | Follow @CarlyHFierce
> News flash for biopharma bosses: More than half your employees want to leave. Story
> Cost-conscious payers are eyeing higher prices on diabetes drugs. Report
> Do testosterone meds boost heart attack risks? FDA asks advisory panels to weigh the data. Article
> Touting a Q2 beat and strong Opsumit launch, Actelion CEO dismisses takeover chatter. More
Biotech Research News
> Top 15 NIH-funded disease areas. Report
> Simulated human heart aims to screen drugs for adverse effects. More
> First U.S.-acquired chikungunya case detected. Item
> Simulated human heart aims to screen drugs for adverse effects. Article
> Enzyme may provide new target for Alzheimer's disease. Story
Pharma Manufacturing News
> FedEx to fight charges it was key link in supply chain for illegal drugs. News
> FDA again warns that Texas compounder's products may not be sterile. Item
> GSK, J&J push for genetic engineering of opium. More
> American Health recalls epilepsy drug and ibuprofen over possible tablet switch. Story
> Lilly to cut 100 production jobs in Indianapolis, but workers get shot at others. Article